Li, Huayi
Peng, Zikun
Zhu, Jianqing
Zhao, Weidong
Huang, Yi
An, Ruifang
Zheng, Hong
Qu, Pengpeng
Wang, Li
Zhou, Qi
Wang, Danbo
Lou, Ge
Wang, Jing
Wang, Ke
Kong, Beihua
Xie, Xing
Yin, Rutie
Low, John
Rozita, Abdul Malik
Sen, Lim Chun
Meng, Yong Chee
Kiong, Kho Swee
Liu, Jihong
Liang, Zhiqing
Lv, Weiguo
Zhu, Yaping
Hu, Weiguo
Sun, Wei
Su, Jingya
Wang, Qiqi
Zang, Rongyu
Ma, Ding
Gao, Qinglei http://orcid.org/0000-0002-9448-3423
Funding for this research was provided by:
AstraZeneca
Article History
Received: 5 October 2023
Accepted: 29 April 2024
First Online: 16 May 2024
Declarations
:
: This study was approved by the national regulatory authority and the respective local ethics committees at each participating institution [(2018)-(3)-No.4 for the leading site], and this study (NCT03534453) was conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: J. Su and Q. Wang are employees of AstraZeneca. All remaining authors have declared no potential conflicts of interest.